Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atrasentan in metastatic HRPC
NCT00036543Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- May 2001
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Atrasentan with Placebo (2 arms). Primary endpoint: Time to Disease Progression. Started May 2001; status: completed.
02
Drugs
atrasentan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00036543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00036543.